Start here
- Direct answers (FAQ)What is TOL, is it FDA approved, where is it available, eligible cancers, cost, evidence, side effects, intake.
- Submit an intake requestClinical eligibility review within three to five business days.
- Why FixCancersClinical comparison vs. integrative wellness and off-label immunotherapy clinics.
Main pages
- HomepageHero, mechanism visuals, three paths, locations, FAQ.
- Answers / FAQTop patient questions with FAQ schema.
- Why FixCancersSide-by-side clinical comparison matrix.
- Literature13 peer-reviewed papers, patent, white papers.
- Financial resourcesMulti-jurisdiction funding pathways.
Compliance
- Regulatory disclosures20-section FDA, FTC, HIPAA tour.
- Investigational therapy statement21 CFR Part 312 framework.
- United States access pathwaysClinical trials, expanded access, Right to Try.
- HIPAA and PHI handling
- Privacy policyGDPR, CCPA, Australia Privacy Act.
- Terms of useTexas-governed.
Downloads
- Comprehensive briefing (HTML)Mechanism, digoxin in oncology, case studies, protocol, jurisdictional access.
- Biophysics & immune engineering (PDF, 16 MB)14-page white paper.
- The aggression paradox (PDF, 10 MB)Companion white paper.
Cross-site
- FixCancer.orgSister site. Canonical technical TOL documentation.
- Procedure (FixCancer.org)Drug, device, full clinical protocol.
- Literature (FixCancer.org)
- Spanish version
- CORE Medical, TijuanaNamed Mexico partner facility.
Visual assets
Machine readable
- XML sitemapFor search engines.
- robots.txtCrawler policy.
- llms.txtAI-search ingest standard.
- llms-full.txtExtended LLM context.
- site.webmanifestPWA manifest.